ClinicalTrials.gg
RecruitingNCT05005403Updated Jun 23, 2026

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

A Phase 1 interventional study of Azirkitug and Budigalimab in Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Micro Satellite Stable Colorectal Cancer, sponsored by AbbVie. Recruiting at 48 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
694
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 48 studies in Carcinoma, Non-Small-Cell Lung by AbbVie — 8 open to participants now, 14 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · AbbVie.

Planned enrollment
4th of 46
694 · median 135
Started
2021
with 2 others
Phase 1
21 of 48
2 open now
Primary completion
2027-07
later than 4 of 13 live
Registered
36th of 48
by date

Among the 48 studies in Carcinoma, Non-Small-Cell Lung by AbbVie, this one is the 4th largest by planned enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2021, is one of 21 in phase 1, reaches primary completion later than 4 of the 13 other live ones, and was the 36th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 48 studies in Carcinoma, Non-Small-Cell Lung by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Carcinoma, Non-Small-Cell Lung by AbbVie, or all of them as a file.
02

Study summary

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which cancer cells form in the tissues of the head and neck. The purpose of this study is to assess adverse events and pharmacokinetics of azirkitug as a monotherapy and in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan.

Bevacizumab is an approved product, while budigalimab, azirkitug, and telisotuzumab adizutecan are investigational drugs being developed for the treatment of NSCLC, HNSCC, and other solid tumors. Study doctors put the participants in groups called treatment arms. The maximum-tolerated dose (MTD)/maximum administered dose (MAD) of azirkitug will be explored. Each treatment arm receives a different dose of azirkitug in monotherapy and in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan. Approximately 694 adult participants will be enrolled in the study across approximately 80 sites worldwide.

Participants will receive azirkitug as a monotherapy or in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan as an Intravenous (IV) Infusion for an estimated treatment period of up to 2 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Non-Small Cell Lung Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Micro Satellite Stable Colorectal Cancer
  • Gastric/Esophageal Cancer
  • High-Grade Serous Ovarian Cancer
  • Pancreatic Cancer
  • Triple Negative Breast Cancer

Keywords

  • Non-Small Cell Lung Cancer
  • NSCLC
  • Head and Neck Squamous Cell Carcinoma
  • HNSCC
  • Solid Tumors
  • Budigalimab
  • ABBV-181
  • ABBV-514
  • Micro Satellite Stable Colorectal Cancer
  • MSS-CRC, Gastric Cancer
  • Esophageal Cancer
  • GEA
  • GEJ
  • High-Grade Serous Ovarian Cancer
  • HGSOC
  • Pancreatic Cancer, PDAC
  • Triple Negative Breast Cancer
  • TNBC
  • Telisotuzumab Adizutecan
  • ABBV-400
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pre Treatment or archive tissue within 6 months without intervening treatment
  • (ECOG) performance status of \<= 0 or 1 and a of >= 3 months.
  • per (RECIST)
  • Laboratory values meeting criteria outlined in the protocol
  • NSCLC - Advanced or progressed on standard of care (SOC) including chemotherapy and prior anti-PD-(L)1 antibody (separately or in combination). Actionable gene alterations are eligible if failed targeted therapeutic options.
  • HSNCC - Advanced/metastatic progressed on platinum and /PD-LI in recurrent or metastatic setting.
  • Micro Satellite Stable Colorectal Cancer (MSS-CRC) - Progressed on Oxaliplatin, Irinotecan, a fluoropyrimidine, anti-EGFR, VEGF or VEGFR therapies, BRAFV600E or , other targetable mutations targeted with locally approved therapy, TAS-102, Regorafenib and not MSI-h or MMR-deficient
  • Gastric and Gastroesophageal Junction adenocarcinoma (GEA) - Advanced/metastatic progressed on at least 1 prior cytotoxic chemotherapeutic regimen and if applicable immune checkpoint inhibitor and/or HER2 therapy
  • High-Grade Serous Ovarian Cancer (HGSOC) - Progressed serous epithelial ovarian, fallopian tube or primary peritoneal cancer post SOC and not eligible for surgical resection. Platinum resistant cannot have >5 .
  • Pancreatic Adenocarcinoma (PDAC) - Advanced/metastatic progressed after SOC. Includes adenosquamous carcinoma and post-Whipple.
  • Triple Negative Breast Cancer (TNBC) - Progressed after 1 or 2 systemic therapy that must have included taxane and treatment naïve to immunotherapy targeting T-cell co-stimulation

Exclusion criteria

Exclusion Criteria:

  • Pancreatic Ductal Adenocarcinoma (PDAC) - Excludes neuroendocrine or acinar pancreatic carcinoma and participants with coagulopathy or at risk of or history of Deep vein thrombosis (DVT)/PE
  • No major surgery within 28 days prior to dosing
  • No active /immunodeficiency disease with limited exceptions
  • Combination treatment excludes participants treated with anti-programmed cell death protein 1()/Programmed cell death ligand 1 (PD-L1) who had immune mediated toxicity G3 or greater, interstitial lung disease, or Combination treatment may also require no significant cardiac deficiencies and/or events
  • Pregnancy
  • Excluded medications include anticancer therapy within 5 half-live or 28 days (whichever is shorter), agent targeting Chemokine Receptor (CCR)8, , medication with limited exceptions
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
694 participants (estimated)

Study arms

  • Experimental
    Part 1 Dose Escalation: Azirkitug

    Participants will receive Azirkitug.

    Drug: Azirkitug

  • Experimental
    Part 1 Dose Escalation: Azirkitug + Budigalimab

    Participants will receive Azirkitug in combination with budigalimab.

    Drug: Azirkitug · Drug: Budigalimab

  • Experimental
    Part 2 Dose Expansion: Azirkitug

    Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion.

    Drug: Azirkitug

  • Experimental
    Part 2 Dose Expansion: Azirkitug + Budigalimab

    Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion in combination with budigalimab.

    Drug: Azirkitug · Drug: Budigalimab

  • Experimental
    Part 3 Dose Expansion: Azirkitug + Budigalimab

    Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion in combination with budigalimab.

    Drug: Azirkitug · Drug: Budigalimab

  • Experimental
    Part 4 Dose Expansion: Azirkitug

    Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion.

    Drug: Azirkitug

  • Experimental
    Part 4 Dose Expansion: Azirkitug + Budigalimab

    Participants will receive Azirkitug in combination with budigalimab.

    Drug: Azirkitug · Drug: Budigalimab

  • Experimental
    Part 4 Dose Optimization and Randomization: Azirkitug

    Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion.

    Drug: Azirkitug

  • Experimental
    Part 4 Dose Optimization & Randomization Azirkitug+Budigalimab

    Participants will receive Azirkitug in combination with budigalimab.

    Drug: Azirkitug · Drug: Budigalimab

  • Experimental
    Part 5 Dose Expansion: Azirkitug + Budigalimab

    Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion in combination with budigalimab.

    Drug: Azirkitug · Drug: Budigalimab

  • Experimental
    Part 6 Dose Expansion: Azirkitug + Budigalimab

    Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion in combination with budigalimab.

    Drug: Azirkitug · Drug: Budigalimab

  • Experimental
    Part 7 Dose Expansion: Azirkitug + Budigalimab

    Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion in combination with budigalimab.

    Drug: Azirkitug · Drug: Budigalimab

  • Experimental
    Part 8 Safety Lead In: Azirkitug + Bevacizumab

    Participants will receive Azirkitug in combination with bevacizumab.

    Drug: Azirkitug · Drug: Bevacizumab

  • Experimental
    Part 8 Dose Expansion: Azirkitug + Bevacizumab

    Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion in combination with bevacizumab.

    Drug: Azirkitug · Drug: Bevacizumab

  • Experimental
    Part 9 Dose Expansion: Azirkitug + Budigalimab

    Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion in combination with budigalimab.

    Drug: Azirkitug · Drug: Budigalimab

  • Experimental
    Part 10 Safety Lead In: Azirkitug + Telisotuzumab Adizutecan

    Participants will receive Azirkitug in combination with telisotuzumab adizutecan.

    Drug: Azirkitug · Drug: Telisotuzumab Adizutecan

  • Experimental
    Part 10 Dose Expansion: Azirkitug+Telisotuzumab Adizutecan

    Participants will receive Azirkitug at recommended dose determined in the safety lead in portion in combination with telisotuzumab adizutecan.

    Drug: Azirkitug · Drug: Telisotuzumab Adizutecan

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AE)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to 2 Years

  2. Maximum Observed Serum Concentration (Cmax) of Azirkitug

    Maximum Observed Serum Concentration (Cmax) of azirkitug.

    Time frame: Up to 2 Years

  3. Time to Maximum Observed Serum Concentration (Tmax) of Azirkitug

    Time to maximum Observed Serum Concentration (Tmax) of azirkitug.

    Time frame: Up to 2 Years

  4. Terminal Elimination Half-Life (t1/2) of Azirkitug

    Terminal elimination half-life (t1/2) of azirkitug.

    Time frame: Up to 2 Years

  5. Area Under the Serum Concentration Versus Time Curve (AUC) of Azirkitug

    Area under the serum concentration versus time curve (AUC) of azirkitug.

    Time frame: Up to 2 Years

  6. Azirkitug Antidrug Antibody (ADA)

    Incidence and concentration of azirkitug anti-drug antibodies.

    Time frame: Up to 2 Years

  7. Azirkitug Neutralizing Antidrug Antibody (nADA)

    Incidence and concentration of azirkitug neutralizing anti-drug antibodies.

    Time frame: Up to 2 Years

  8. Cmax of Budigalimab

    Cmax of budigalimab.

    Time frame: Up to 2 Years

  9. Tmax of Budigalimab

    Tmax of budigalimab.

    Time frame: Up to 2 Years

  10. t1/2 of Budigalimab

    t1/2 of budigalimab.

    Time frame: Up to 2 Years

  11. AUC of Budigalimab

    AUC of budigalimab.

    Time frame: Up to 2 Years

  12. Budigalimab ADA

    Incidence and concentration of budigalimab ADA.

    Time frame: Up to 2 Years

  13. Budigalimab nADA

    Incidence and concentration of budigalimab nADA.

    Time frame: Up to 2 Years

  14. Cmax of Telisotuzumab Adizutecan

    Cmax of telisotuzumab adizutecan.

    Time frame: Up to 2 Years

  15. Tmax of Telisotuzumab Adizutecan

    Tmax of telisotuzumab adizutecan.

    Time frame: Up to 2 Years

  16. t1/2 of Telisotuzumab Adizutecan

    t1/2 of telisotuzumab adizutecan.

    Time frame: Up to 2 Years

  17. AUC of Telisotuzumab Adizutecan

    AUC of telisotuzumab adizutecan.

    Time frame: Up to 2 Years

  18. Telisotuzumab Adizutecan ADA

    Incidence and concentration of telisotuzumab adizutecan ADA.

    Time frame: Up to 2 Years

  19. Telisotuzumab Adizutecan nADA

    Incidence and concentration of telisotuzumab adizutecan nADA.

    Time frame: Up to 2 Years

07

Study locations

47 of 48 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Jul 2027, 68 months after the start.

Of 473 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 68 months is above that.

Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2021
First posted
Aug 13, 2021
StartActual
Nov 1, 2021
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05005403
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Aug 13, 2021
Start date
Nov 1, 2021
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jun 23, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion